Search

Your search keyword '"Talebi, Atefeh"' showing total 10 results
Start Over Author "Talebi, Atefeh" Publication Year Range This year
10 results on '"Talebi, Atefeh"'

2. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial

Author

Kondo, Toru, Mogensen, Ulrik M., Talebi, Atefeh, Gasparyan, Samvel B., Campbell, Ross T., Docherty, Kieran F., de Boer, Rudolf A., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Sabatine, Marc S., Bengtsson, Olof, Sjöstrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.

Published
2024
Full Text
View/download PDF

3. Measuring congestion with a non‐invasive monitoring device in heart failure and haemodialysis: CONGEST‐HF

Author

Curtain, James P., primary, Talebi, Atefeh, additional, McIntosh, Alasdair, additional, McConnachie, Alex, additional, O'Donnell, Joanne, additional, Welsh, Paul, additional, Osmanska, Joanna, additional, Lee, Matthew M.Y., additional, Sonecki, Piotr, additional, Akl, Tony, additional, Seo, Joohyun, additional, Gopinathan, Venugopal, additional, Hurwitz, Jed, additional, Thiagarajan, Srikanth, additional, Pettit, Stephen, additional, Kalra, Paul R., additional, Patel, Rajan K., additional, Mark, Patrick B., additional, Lang, Ninian N., additional, McMurray, John J.V., additional, Petrie, Mark C., additional, Gardner, Roy S., additional, and Jhund, Pardeep S., additional

Published
2024
Full Text
View/download PDF

4. Adherence to dietary recommendations by socioeconomic status in the United Kingdom biobank cohort study

Author

Carrasco-Marín, Fernanda, primary, Parra-Soto, Solange, additional, Bonpoor, Jirapitcha, additional, Phillips, Nathan, additional, Talebi, Atefeh, additional, Petermann-Rocha, Fanny, additional, Pell, Jill, additional, Ho, Frederick, additional, Martínez-Maturana, Nicolás, additional, Celis-Morales, Carlos, additional, Molina-Luque, Rafael, additional, and Molina-Recio, Guillermo, additional

Published
2024
Full Text
View/download PDF

5. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction

Author

McDowell, Kirsty, primary, Kondo, Toru, additional, Talebi, Atefeh, additional, Teh, Ken, additional, Bachus, Erasmus, additional, de Boer, Rudolf A., additional, Campbell, Ross T., additional, Claggett, Brian, additional, Desai, Ashkay S., additional, Docherty, Kieran F., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S. P., additional, Martinez, Felipe, additional, Simpson, Joanne, additional, Vaduganathan, Muthiah, additional, Jhund, Pardeep S., additional, Solomon, Scott D., additional, and McMurray, John J. V., additional

Published
2024
Full Text
View/download PDF

7. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.

Author

Yang, Mingming, Kondo, Toru, Talebi, Atefeh, Jhund, Pardeep S., Docherty, Kieran F., Claggett, Brian L., Vaduganathan, Muthiah, Bachus, Erasmus, Hernandez, Adrian F., Lam, Carolyn S.P., Inzucchi, Silvio E., Martinez, Felipe A., de Boer, Rudolf A., Kosiborod, Mikhail N., Desai, Akshay S., Køber, Lars, Ponikowski, Piotr, Sabatine, Marc S., Solomon, Scott D., and McMurray, John J.V.

Subjects
BRAIN natriuretic factor, HEART failure patients, VENTRICULAR ejection fraction, QUALITY of life, DAPAGLIFLOZIN
Abstract

Aims: Although much is known about the usefulness of heart failure (HF)‐specific instruments for assessing patient well‐being, less is known about the value of generic instruments for the measurement of health‐related quality of life (HRQL) in HF. The aim of this study was to assess the relationship between the EuroQol 5‐dimension 5‐level (EQ‐5D‐5L) visual analogue scale (VAS) and index scores, clinical characteristics, and outcomes in patients with HF and the effect of dapagliflozin on these scores. Methods and results: We performed a patient‐level pooled analysis of the DAPA‐HF and DELIVER trials, which investigated the effectiveness and safety of dapagliflozin in patients with HF and reduced ejection fraction (HFrEF) and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), respectively. Patients reporting higher (better) EQ‐5D‐5L VAS and index scores had a lower prevalence of comorbidities, including atrial fibrillation and hypertension, than patients with a worse score. They were also more likely to have better investigator‐reported (New York Heart Association class) and patient‐self‐reported (Kansas City Cardiomyopathy Questionnaire) health status and lower median N‐terminal pro‐B‐type natriuretic peptide levels. Compared to patients with the lowest scores (Q1), those with higher EQ‐5D‐5L VAS scores had better outcomes: the hazard ratio for the composite of cardiovascular death or worsening HF was 0.81 (95% confidence interval 0.72–0.91) in Q2, 0.74 (0.65–0.84) in Q3, and 0.62 (0.54–0.72) in Q4. The risk of each component of the composite outcome, and all‐cause death, was also lower in patients with better scores. Similar findings were observed for the index score. Treatment with dapagliflozin improved both EQ‐5D‐5L VAS and index scores across the range of ejection fraction. Conclusions: Both higher (better) EQ‐5D‐5L VAS and index scores were associated with better outcomes. Dapagliflozin treatment improved EQ‐5D‐5L VAS and index scores, irrespective of ejection fraction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. THE EFFECT OF DAPAGLIFLOZIN ON DAYS OF FULL HEALTH LOST DUE TO DEATH, HOSPITALIZATION, AND IMPAIRED WELL-BEING IN DAPA-HF

Author

Kondo, Toru, Mogensen, Ulrik Madvig, Talebi, Atefeh, Gasparyan, Samvel, campbell, ross, Docherty, Kieran F., De Boer, Rudolf A., Inzucchi, Silvio E., K⊘ber, Lars, Kosiborod, Mikhail, Martinez, Felipe A., Sabatine, Marc Steven, Bengtsson, Olof, Sjoestrand, Mikaela, Vaduganathan, Muthiah, Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results